Walking the Isobole of Drug Interaction
Information source: University Medical Center Groningen
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hemodynamic Instability; Disorder of Oxygen Transport; Interaction; Anesthesia
Intervention: Group A propofol + remifentanil (Drug); Group B propofol + remifentanil (Drug); Group C propofol + remifentanil (Drug); group D propofol + remifentanil (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University Medical Center Groningen Official(s) and/or principal investigator(s): Hugo EM Vereecke, MD, PhD, Principal Investigator, Affiliation: University Hospital Medical center, university of groningen
Overall contact: Hugo EM Vereecke, MD, PhD, Email: h.e.m.vereecke@umcg.nl
Summary
The investigators study whether four equipotent combinations of propofol and remifentanil
(as predicted by interaction models for "tolerance of laryngoscopy") result in identical
haemodynamic conditions, independent of their relative different balance between the
concentration of propofol and remifentanil.
Clinical Details
Official title: Walking the Isobole of Drug Interaction: Comparison of Hemodynamic Effects, Cerebral and Tissue Oxygenation for 4 Equipotent Combinations of Propofol and Remifentanil
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)
Primary outcome: Blood pressure
Secondary outcome: Electro Encephalographic derived indices of anesthetic depthCerebral and tissue oxygenation Heart rate Probability of tolerance to laryngoscopy Cardiac index
Detailed description:
In anesthesia, the synergistic interaction between hypnotics and opioids is applied daily to
give adequate anesthesia and analgesia at significantly lower doses compared with the ones
needed if only one drug was given to reach the same effect. A lot of research has been done
to quantify these interactions with a focus on the desired effects (Tolerance of
laryngoscopy, tolerance of shake and shout etc...), but the simultaneous interaction on the
unwanted side effects is less well described. The response surface model of Bouillon et al.
and other models predict combinations of propofol and remifentanil effect-site
concentrations that lead to an equipotent desired effect. Due to the availability of the
models, the anesthesiologists now could use the knowledge on interactions to target
specific effects more accurately, using predefined equipotent combinations of drugs: for
instance, a desirable 90% probability of tolerance of laryngoscopy (TOL90) in the population
can be reached through either a high propofol/low remifentanil combination, but equally well
through a low propofol-high remifentanil combination.
However, at this time it is not known whether some of the combinations of propofol and
remifentanil have a favorable hemodynamic stability compared to other equipotent
combinations. The researcher in this study want to determine whether equipotent combinations
of remifentanil and propofol (all deliberately selected to evoke 90% probability of
"tolerance to laryngoscopy"), result in different effects on the undesired side effects of
anesthetics, such as hemodynamic instability (hypotension, changes in heart rate or cardiac
output), decreases in cerebral or tissue oxygenation (both measured with near infrared
spectroscopy).
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Written informed consent
- General anesthesia required for the procedure
- Age: 18 years and older
- American Society of Anesthesiologists (ASA) physical status I to III
Exclusion Criteria:
- Refusal to participate in this study
- Contra-indications for the use of propofol or remifentanil
- BMI > 35 kg/m2
- Central nervous system disorders (i. e. cerebrovascular accident, dementia, seizures,
psychiatric disorders)
- Relevant hepatic disease (Child B or higher)
- Regular use of medication that affects the central nervous system (i. e.
benzodiazepines, antidepressants, antipsychotics, antiepileptic drugs)
- Use of alpha-agonists or beta-blockers
- Overt signs of alcohol abuse
- Use of preoperative benzodiazepines (on the day of the study)
- Beta blockers eye drips
- Overt signs of Drugs abuse
Locations and Contacts
Hugo EM Vereecke, MD, PhD, Email: h.e.m.vereecke@umcg.nl
University Medical Center Groningen, Groningen 9713EZ, Netherlands; Recruiting
Additional Information
Starting date: February 2014
Last updated: December 9, 2014
|